• Zelluna dosed the first patient in ZIMA-101, a first-in-human Phase 1 trial of its lead TCR-NK therapy ZI-MA4-1.
• The study tests an off-the-shelf cell therapy in advanced MAGE-A4-positive solid tumors, marking the platform’s first clinical evaluation.
• No results have been presented; initial clinical data are expected from mid-2026.
• The first dosing shifts the program into patient testing, a key step toward validating safety and early signs of activity.
• Two UK sites are active, supporting broader recruitment across four tumor indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zelluna ASA published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.